Quick Update for 89bio (ETNB) Investors

89bio shot up 6.14% Friday, trading between a high of $14.45 and a low of $13.0 per share. Yesterday the stock finished at $13.35 per share, compared to an average analyst target price of $25.13.

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardiometabolic diseases. The small-cap pharmaceutical preparations company is based in the United States, and over the last twelve months it has returned a dividend yield of 0.0%. 89bio has trailing twelve months earnings per share (EPS) of -4.08, which at today's prices amounts to a price to earnings (P/E) ratio of -3.47.

Based on its expected future earnings growth, the company has a price to earnings growth (PEG) ratio of None. Usually a PEG ratio between zero and one indicates a potentially undervalued company.

ETNB has a revenue per share ratio of 0 and an enterprise value to revenue ratio of -, based on its total revenue of $None. The company's revenues have a year-on-year growth rate of 0.0%, compared to a YoY growth rate of 0.0% for its earnings.

Here's an overview of the company's gross margins in recent years:


The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.